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Abstract Polycystin-1 (PC-1) is a member of a novel family of
proteins that have a multidomain structure. Although the C-
terminal intracellular segments have been extensively studied,
mainly with respect to their putative involvement in cell signal-
ling, the potential function of the extracellular domains has
received less attention. Mutations in PC-1 result in autosomal
dominant polycystic kidney disease (ADPKD) which is charac-
terised by perturbation of transport resulting in £uid accumu-
lation, cell proliferation and modi¢cation of the extracellular
matrix. The possibility that the interaction of a component of
the extracellular matrix or some external factor with PC-1 may
be important in the initiation or progression of ADPKD cannot
currently be ruled out. The purpose of this review is to assess
current evidence for the function of the PC-1 extracellular do-
mains, and their potential implications for ADPKD.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The localisation of the PKD1 gene to chromosome 16p13.3
[1] and the subsequent characterisation of its protein product,
polycystin-1 (PC-1), heralded an intense period of research.
While many aspects of PC-1 biology, including its relationship
with the related gene product polycystin-2, have been well
studied by di¡erent groups (comprehensively reviewed in
[2,3]), the extracellular PC-1 N-terminal received less atten-
tion. The PKD1 gene product is an integral membrane protein
(PC-1) that possesses multiple secondary structural motifs [4].
The putative extracellular domain sequences of both the hu-
man and mouse PKD1 gene product sequences are similar and
both exhibit homology with the product of the Fugu rupribes
PKD1 gene [5]. The evolutionary conservation of these do-
mains indicates that they may play an important role in the
function of PC-1.
There is now evidence to suggest that three of the PC-1
extracellular protein motifs are functional [6^9]. This review
aims to focus on the possible functions of the PC-1 extracel-
lular domains, and to outline their potential contribution to
the function of this multifaceted molecule.
2. Domain organisation and potential function of PC-1
The PKD1 gene product, PC-1, is a large 4302 amino acid
protein predicted to possess an extracellular region of approx-
imately 2579 residues, multiple transmembrane domains, and
a highly charged 225 residue cytoplasmic carboxy-terminus
[4]. The recent expression of full-length recombinant PC-1
has con¢rmed that the protein possesses a predicted mass of
approximately 460 kDa, and a glycosylated mass of 520 kDa
[10]. Full-length PC-1 has also been immunoa⁄nity-puri¢ed
from the 293 embryonic kidney epithelial cell line [11]. The
PKD1 coding region begins with a hydrophobic 23 amino acid
sequence that displays the characteristics of a signal peptide.
This, coupled with the fact that PC-1 contains several well-
de¢ned peptide motifs found in extracellular locations in other
cells, led to the suggestion that almost two thirds of the pro-
tein lie outside the cell [4,12], and that the N-terminal portion
of PC-1 might be capable of binding ligands in the extracel-
lular compartment [13]. The extracellular motifs are detailed
in Fig. 1, and are discussed in the following sections.
3. Leucine-rich repeats
Two complete B-type leucine-rich repeats (LRRs) are en-
coded by PKD1 exons 2 and 3 [1,4,12]. LRRs are character-
ised by the occurrence of a 24 amino acid consensus sequence,
containing leucine or other aliphatic amino acids at key posi-
tions. The other amino acids distributed among the hydro-
phobic residues tend to be hydrophilic and it is thought that
LRRs fold in an amphipathic structure [14]. B-type repeats,
like those in PC-1, contain an asparagine at position 10.
LRRs are usually £anked by cysteine-rich domains that are
classi¢ed as being either amino- or carboxy-£anking [15]. The
PC-1 £anking regions are encoded by PKD1 exons 1 and 4
[4,12].
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LRRs are found in a functionally and evolutionarily diverse
set of proteins. The presence of such a motif is thought to
provide a structural framework for the formation of protein^
protein interactions, and it has been postulated that most
proteins that contain LRRs are involved in protein^protein
recognition processes [15]. Recently, Malhas et al. [9] used a
PC-1 GST-LRR protein and demonstrated that the PC-1
LRRs bound the extracellular matrix (ECM) proteins collagen
I, laminin and ¢bronectin. The fusion protein also interacted
strongly with unidenti¢ed components of cyst £uid from au-
tosomal dominant polycystic kidney disease (ADPKD) pa-
tients.
Over half of all proteins containing LRRs are involved in
signal transduction pathways [15]. The PC-1 LRR fusion pro-
tein was shown to inhibit the proliferation of human brain
astrocytoma and 293 cells, even under conditions that would
otherwise be expected to stimulate proliferation [9]. There are
two possible explanations for the PC-1 involvement in devel-
opment and cystogenesis. The ¢rst assumes that PC-1 is part
of a pathway that induces cell proliferation in response to
binding ECM proteins. The addition of LRR fusion proteins
to cells in culture competes with the LRRs in PC-1 resulting
in the observed decrease in cell proliferation. The second as-
sumes that the LRRs of PC-1 bind to a cell surface receptor
Fig. 1. Predicted structure of the PKD1 gene product, PC-1, showing the positions and predicted functions of the extracellular protein motifs
and domains. All domain positions were obtained using SwissProt using the accession number Q15141. Not to scale.
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on adjacent cells to reduce the rate of proliferation. Both
explanations suggest that the PC-1 LRRs may be involved
in cell^matrix interactions and might provide means of con-
trolling the cell’s proliferative state.
4. WSC domain
A putative WSC domain, named after the cell wall integrity
and stress component proteins 1^4 found in Saccharomyces
cerevisiae, is found in PC-1 between the LRRs and the ¢rst
PKD domain (see below) [16]. While the function of WSC
domains is not known, the S. cerevisiae WSC proteins have
been shown to act as upstream regulators of the stress-acti-
vated protein kinase C1^mitogen-activated protein kinase cas-
cade, and are required for the heat shock response and for
maintenance of cell wall integrity [17]. The similarity of the
PC-1 WSC domain with those from a hypothetical sulpho-
transferase protein, and a L-1,3-exoglucanase from Trichoder-
ma harzianum [18], has led to the suggestion that it may be
involved in carbohydrate binding [16]. Indeed the proximity of
the WSC domain to the C-type lectin domain may suggest
that this region has a role involving interaction with carbohy-
drate, possibly acting as a regulator of stress-activated path-
ways if the WSC domain behaves in a similar manner to that
seen in S. cerevisiae WSC proteins.
5. C-type lectin domain
Analysis of the deduced amino acid sequence from exons 6
and 7 of the PKD1 gene shows a high level of homology with
a C-type lectin domain [4,12]. These motifs are compactly
folded protein modules of between 115 and 130 amino acids,
and are characterised by the occurrence of a common se-
quence motif of 14 invariant and 18 highly conserved residues
[19]. C-type lectin carbohydrate recognition domains bind car-
bohydrate in a calcium-dependent manner [19]. The C-type
lectin family binds a wide range of carbohydrate ligands,
with di¡erent subtypes displaying a⁄nity for di¡erent classes
of carbohydrate, and C-type lectins mediate many di¡erent
biological processes in vivo, including cell signalling and exo-
cytosis [20].
The PC-1 C-type lectin domain has been expressed as a
GST fusion protein which bound carbohydrate in a Ca2þ-de-
pendent manner in vitro, and interacted with di¡erent types of
carbohydrate matrices [7]. Of interest to the current discussion
is the observation that the PC-1 C-type lectin fusion protein
bound to di¡erent ECM proteins, especially collagens I and
IV. These interactions were Ca2þ-dependent and raise the in-
teresting possibility that the PC-1 C-type lectin domain inter-
acts with these ligands in vivo. However, as with all functional
studies using fusion proteins, care must be taken to ensure
that the recombinant protein assumes the correct fold, and
that in vitro observations using isolated domains can be con-
¢rmed using approaches where the domain is present in the
context of the whole protein.
6. LDL region
A low-density lipoprotein-A domain (LDL-A) is encoded
by exon 10 of the PKD1 gene [12]. LDL-A domains are cys-
teine-rich sequences of about 40 amino acid residues. They are
present in extracellular portions of many proteins and are
thought to be ligand-binding regions in LDL receptor-related
molecules, predominantly because of their hydrophobic na-
ture [21]. To date, no studies have focussed on the potential
binding partners of the PC-1 LDL-A domain, perhaps be-
cause there is some confusion as to whether it occurs in PC-
1 at all. The initial study by Hughes et al. [4] and the subse-
quent comparative study by Sandford et al. [5] failed to iden-
tify such a motif.
7. PKD repeats
A repeating module of approximately 80 amino acids,
thought to represent a distinct protein family, is encoded by
the PKD1 gene. Both the human and F. rupribes PKD1 genes
are predicted to contain 16 copies of this ‘PKD domain’, one
in exon 5, and 15 arranged in a tandem array in exons 11^15
[4,5]. Nuclear magnetic resonance structural analysis of the
¢rst PKD domain from human PC-1 revealed that it forms
a characteristic Ig-like fold [22]. Similar patterns of amino
acid residues in domains 2^16 also led to the prediction that
these possess the same secondary structure as the ¢rst PKD
domain [23]. Initial analysis of the PC-1 primary sequence
showed that at least two of the PKD domains possess signi¢-
cant evolutionary similarity with the I-set of Ig domains,
found in the cell adhesion molecules and cell adhesion recep-
tors [4,24]. However, based on their structural data it was
proposed that the PKD domains are completely distinct
from this family [23]. What is clear is the importance of the
PKD domains for PC-1 function, and perhaps domain 10 in
particular [23]. The demonstration that the PKD domains
interacted with each other in a calcium-dependent manner in
vitro provided direct evidence that they may be important
mediators of cell^cell interactions [8]. This study also showed
that antibodies to these domains disrupt cell^cell interactions
of Madin^Darby canine kidney (MDCK) cells, leading to the
suggestion that loss of PKD domain interactions might be an
important step in cyst formation in ADPKD. Additionally,
when used as competitive inhibitors, peptides derived from
the PKD repeats prevented normal ureteric bud branching
in cultured kidney remnants [6]. These observations, coupled
with the developmental expression patterns of PC-1 [25], sug-
gest that PC-1, and in particular the activity of the PKD
repeats, is important for normal development of the kidney.
8. REJ domain
The sea urchin receptor for egg jelly (suREJ) is a 210 kDa
sperm membrane glycoprotein, and functions as a regulator of
ion transport in the acrosome reaction. A large part of the
REJ shares extensive sequence identity with PC-1 in a region
downstream of PKD domains 2^16 [26]. This region, which
has been termed the REJ module, is encoded by PKD1 exons
15^27 [5]. More recently a human homologue of suREJ,
termed PKDREJ, has been identi¢ed, which shares sequence
similarity with PC-1 over 2000 amino acids, in the region
corresponding to the REJ module [27]. The discovery of the
REJ module supports the idea that, like suREJ, PC-1 func-
tions to support Ca2þ in£ux [16,26,28].
9. GPS motif
PC-1 is also predicted to contain a G protein-coupled re-
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ceptor proteolytic site (GPS) [16]. This domain is immediately
downstream of the REJ module and also occurs in suREJ.
Also known as latrophilin/CL-1-like domains, GPS domains
are known to be sites of proteolytic cleavage in other proteins
[29]. Despite only possessing one of the two putative disul-
phide bridges found in the CL-1 domains from other proteins
Ponting et al. [16] predicted that PC-1 is endogenously cleaved
at the Leu3048-Thr3049 peptide bond to produce an amino-ter-
minal chain of 3048 amino acids and a carboxy-terminal chain
of 1255 amino acids. The demonstration that suREJ is cleaved
at its GPS domain [30] added weight to the prediction. A
recent study has now shown that PC-1 is indeed cleaved,
most likely at the GPS domain, a process that requires the
adjacent REJ module to be present [31]. Cleavage occurs rap-
idly after synthesis, although most of the N-terminal cleaved
fragment remains at the cell surface. Known ADPKD muta-
tions in the REJ module prevent cleavage and signal trans-
duction through PC-1, leading to the suggestion that cleavage
is vital for PC-1 to exhibit full biological activity, perhaps
through the creation of a novel ligand-binding pocket [31].
What the consequences of cleavage at the GPS domain
would mean for the N-terminal domains in PC-1 remains
unclear at present. The fact that the PKD repeats are in-
volved in mediating both cell^cell contact and renal develop-
ment [6,8] and that the PC-1 LRRs inhibit cell proliferation in
vitro [9] indicate that the extracellular portion of PC-1 is
important for function. In addition, it has been recently dem-
onstrated that mouse PC-1 and polycystin-2 located in the
single non-motile primary cilium on kidney epithelial cells
are important for calcium in£ux in response to physiological
£uid £ow [32]. The use of a blocking antibody raised against
the ¢rst PKD domain of PC-1 abolished this activity, leading
to the suggestion that the N-terminal portion of the PC-1
protein may act as a mechano-£uid stress sensor [31], further
evidence that this region is functionally important, at least
under certain circumstances.
Ectodomain shedding has been observed in a number of
membrane-anchored proteins such as syndecan-1 and -4 [33].
The shed ectodomains of syndecans can still bind to their
ligands and therefore compete for the same ligands as their
membrane-bound proteins [33,34]. Whether protein^protein
and/or protein^carbohydrate interactions mediated by the
N-terminal portion of PC-1 are important post-cleavage re-
mains to be determined.
Fig. 2. Diagram showing the subcellular locations of polycystin-1 (in blue). A: Experimental evidence has been obtained that suggests that PC-
1 exists in a complex with polycystin-2 (in red) and is localised (I) at points of cell^cell contact; (II) at points of cell^matrix contact; and (III)
in primary cilia. Not to scale. B: Immunohistochemical staining for PC-1 showing the membrane distribution of the protein in normal renal
tubular epithelial cells. The antibodies and conditions used are described in Weston et al. [25]. Abbreviations used in the ¢gure: FAK, focal ad-
hesion kinase; Vin, vinculin; T, talin; D, desmosome; K, L, Q, K, L and Q catenin; E-cad, E-cadherin; C, cystin; P, polaris; GPS, G protein-
coupled receptor proteolytic site.
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10. Polycystin subcellular localisation: at least two sides to
every story
The predicted existence of multiple protein motifs towards
the N-terminus of PC-1 [4] o¡ered an insight into potential
aspects of protein function, based on the assumptions that (a)
the domains were active, and (b) they would display similar
characteristics to identical domains that form part of other,
unrelated proteins. However, the variety of protein motifs
seen in the molecule has meant that there has always been
an ambiguity about the location of PC-1 in the cell. There has
never been any doubt about it being an integral membrane
protein but whether it exists at the basal, lateral or even in the
apical membrane has always proved to be less clear cut. The
three do not have to be mutually exclusive and indeed, exper-
imental evidence obtained speci¢cally relating to the behav-
iour of the N-terminal motifs and the identi¢cation of possible
binding/co-localising partners indicates that PC-1 may exist in
at least two distinct membrane locations. If the PC-1 C-type
lectin [7] and/or LRR domains [9] associate with ubiquitous
ECM molecules in vivo, and PC-1 co-localises with K2L1 in-
tegrin in focal clusters [35,36] then clearly PC-1 must exist in
the basal membrane under some circumstances. Similarly, PC-
1 must also exist in the lateral membrane if it co-associates
with E-cadherin and the catenins [37], and desmosomes [38].
The fact that inhibition of the PKD repeats disrupts cell^cell
interactions would also support this view [8]. Furthermore,
more recent evidence also places both human and mouse
PC-1 and lov-1, the Caenorhabditis elegans PC-1 homologue,
in the primary cilia [32,39,40]. Our current knowledge of
where PC-1 is localised within a cell is summarised in Fig. 2.
There is in vitro evidence to suggest that PC-1 may switch
from predominantly basally associated to predominantly lat-
erally associated membrane forms, when subcon£uent cell
monolayers reach con£uence [36], introducing the idea that
the location of PC-1 may perhaps be developmentally con-
trolled. In addition further evidence for temporal regulation
of location has been obtained by Bukanov et al. [41], who by
monitoring hepatocyte growth factor-induced tubulogenesis
from MDCK cysts found that PC-1 is only associated in the
basolateral membrane at points of cell^cell contact at the time
of cell polarisation and lumen formation, and not before.
Using the same model this location was also seen to change
during cystogenesis when a dramatic downregulation in PC-1
mRNA levels was accompanied by a shift in PC-1 to a solely
cytoplasmic distribution [41]. Exactly what the potential role
of PC-1 in these di¡erent subcellular locations is requires fur-
ther investigation.
Long before the identity of PC-1 was known extensive anal-
ysis had revealed that the three classical defects in ADPKD
cyst-lining epithelial cells were altered proliferation, £uid ac-
cumulation and ECM remodelling [42]. These secondary
events assume an even greater importance in view of our
current understanding of the primary events associated with
cystogenesis. Whether an altered expression pattern of PC-1 in
ADPKD directly contributes to any of these remains to be
elucidated. It has been proposed that PC-1 may act to in£u-
ence cell function by controlling both the formation and acti-
vation of key signalling complexes [13]. With this in mind it
will be necessary to identify which extracellular ligands can
initiate polycystin-mediated signalling pathways, in order to
better understand the potential consequences for altered signal
transduction in ADPKD.
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